Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter. (13:27)
Tag Archives: H. Jack West
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer. (8:57)
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting. (9:58)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice. (9:52)
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and where these results fit into management of patients in this setting. (6:38)
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn’t This Tell Us? (BMIC-068)
Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC. (9:41)
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population. (4:12)
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice. (8:03)
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups. (7:21)
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard of care in this setting. (9:08)